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The  expression  of MHC  class  II  antigens  is  not a  constitutive property  of 
nonlymphoid cells, but is dependent on lymphokines, as has been reported for 
routine (1-3) and human monocytes (4), endothelial cells, both in vivo (5, 6) and 
in  vitro  (7,  8),  fibroblasts  (9),  tumor  cells  (10,  1 1),  and  brain  cells  (12).  This 
effect  of lymphokines  on  MHC  class  II  antigen  expression  is  influenced  by 
eicosanoids (13),  corticosteroids (14),  and  by the immunosuppressive drug cy- 
closporine A (5, 6, 8). IFN-y has been suggested (15) as the responsible factor in 
supernatants of activated lymphocytes for antigen expression.  Purified cDNA- 
derived  IFN-3,  possesses  the  capacity  to  induce  expression  of  MHC-class  II 
antigens (4, 7, 9-1 1). 
In our experiments, however, a discrepancy was observed between IFN-3, titers 
in supernatants and the  MHC class  II antigen-inducing capacity. This finding 
suggested that MHC class II antigen expression is not only regulated by IFN-3,, 
but  also  by  a  combination  of  incompletely  defined  mediators  in  leukocyte 
supernatants. 
In our search for the regulatory mechanism in MHC class II antigen expression, 
we studied immunoregulatory factors different from IFN-3,  in supernatants of 
human leukocytes with respect to their MHC class II antigen-inducing capacity. 
Here we describe a  mediator, different from IFN-3,, that induces MHC class II 
antigen expression. This mediator was present in supernatants of human leuko- 
cytes, and its effect appeared  to be potentiated by IFN-3,.  Biochemical analysis 
revealed a  molecular weight of 32 kD. 
Materials and Methods 
Cells.  Human diploid fibroblasts isolated from fetal lung tissue were kindly provided 
by Dr.  Galama, Dept. of Virology, Hospital St. Annadal, Maastricht, The Netherlands. 
Human  large  bowel  adenocarcinoma cells  COLO205  and  Hs703T  were  gifts of Dr. 
Verstijnen,  Dept.  of Pathology,  University of Limburg.  Kidney epithelial  cells  were 
isolated fi'om human kidneys by trypsinization. Two kidneys f?om different donors have 
been  used,  harvested  by our  own  center,  and  for medical reasons  were  rejected  for 
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transplantation  use.  Fibroblasts,  kidney epithelial cells, and tumor cells were cultured in 
DMEM  (Gibco,  Paisley,  United  Kingdom) supplemented  with  10%  heat-inactivated  (30 
rain, 56°C) FCS and antibiotics. 
Reagents.  IL-I was purchased from Genzyme (Boston, MA) as purified natural human 
IL-1. Human cDNA-derived rlFN-y and rlL-2 were kindly provided by Dr. Devos, Ghent, 
Belgium  (16-18).  Mixed  leukocyte culture  supernatants  (MLC-SN)" were  prepared  as 
usual.  Leukocytes  were  prepared  by  buoyant  density  centrifugation  on  Lymphoprep 
(Nyegaard,  Oslo,  Norway) of buffy coats of blood  donors.  Responder  leukocytes,  106 
cells/ml, were cocultured with 4,000 rad x-irradiated stimulator leukocytes,  106 cells/ml, 
ill  RPMI  1640 (Gibco) supplemented  with  10%  human serum and antibiotics.  MLC-SN 
was harvested after 6 d of culture.  For supernatant of lectin-stimulated leukocytes (PHA- 
SN),  leukocytes  106 cells/ml  in medium identical  to medium  for MLC, were stimulated 
with PHA, used as purified PHA (Wellcome, Beckendham, United Kingdom) at 1 #g/ml, 
for 3  d.  Supernatants  of MLC and  PHA-stimulated  leukocytes with  a  [3H]TdR uptake 
>25 times than that of control cultures were used throughout the experiments.  MLC-SN, 
PHA-SN, or supernatants  of unstimulated  leukocytes were centrifuged,  filter  sterilized 
(pore size 0.22 um) and stored in aliquots at -20°C until use. Acid dialysis of supernatants 
was performed against a glycine-HCL buffer of pH 2 for 24 h, followed by dialysis against 
nledium to obtain a neutral pH.  MLC-SN and acid-dialyzed MLC-SN were concentrated 
10-fold by dialysis against PEG 20,000 before IFN-y titers were determined.  IFN-y titers 
in  MLC-SN were determined  in a  virus protection assay with  HEp-2 cells.  In MLC-SN, 
IFN-y titers ranged fi'om 8 to 260 IU/ml. After acid dialysis, virus protection could not 
be detected; titers of IFN-'/were therefore lower than 0.2 IU/ml. For purpose of IFN-'/ 
neutralization by mAb D9D10 (specific for human IFN-'y) twice the amount of anti-IFN 
antibodies necessary for neutralization (as assayed in a virus-protection assay) was used for 
the  supernatants.  For  the  experiment  with  100  IU  rlFN-2¢,  the  amount  of antibody 
necessary to neutralize 200 IU was used. Addition of an irrelevant control mAb, F3-20-7 
(against canine Thy-I  antigens  [19]), in an identical  dilution  of ascites as used for mAb 
D9D 10 had an effect similar to untreated supernatants (data not shown). The hybridoma 
secreting mAb D9D10 (IgG1) was derived through standard procedures.  BALB/c mice 
were  immunized  with  highly  purified  natural  human  IFN-y.  Screening  of the  fusion 
products was based on binding of natural human I FN-y. The antibody D9D 10 binds both 
natural and recombinant IFN-'/. Furthermore, it inhibits the effect of both types of human 
IFN--y in a virus-protection assay. 
Induction  and  Detection  of MHC  Antigens.  Cells  were  incubated  for  3  d  in  culture 
medium  supplemented  with  reagents  to be  tested  for capacity to induce expression  of 
MHC antigens.  Expression  of MHC antigens was studied  with an indirect  immunofluo- 
rescence technique.  The first  layer consisted of mAbs against human  MHC antigens;  a 
second layer of FITC-labeled antiserum against mouse Ig was used (Nordic, Tilburg, The 
Netherlands).  The mAbs Tii22, Tfi36, and Tfi39 (20) (reacting respectively against DQ, 
DR, and DR +  DQ) were kindly provided by Dr. Ziegler, Medizinische Universitfitsklinik, 
Tiibingen,  Federal Republic of Germany. The mAb Genox 3.53 (21), reacting with DQ, 
Medizinische Universitfitsklinik,  was a gift of Dr. W. Bodmer, Imperial Cancer Research 
Fund,  London.  In  addition,  mAb  7.5.10.1  (22),  broadly  reacting  with  MHC  class  II 
antigens,  was  used.  The  mAb  W6/32  (23),  reacting  with  MHC  class  I  antigens,  was 
purchased  from  Serotec  (Blackthorn,  United  Kingdom).  mAb  F3.20.7  (19)  served  as 
control antibody in the immunofluorescence assay. Cells were stained in suspension in the 
presence of 0.1%  BSA and 0.01% azide on ice.  Both layers were incubated for 30 rain, 
followed by three washes at 4°C. Fluorescence was determined with either a fluorescence 
microscope or with a  FACS IV, and cells stained above control were considered positive 
for expression of MHC antigens. 
Biochemical Analysis.  Two antisera were immobilized on CNBr-activated Sepharose 4 
B (Pharmacia Fine Chemicals, Uppsala, Sweden): ascites fluid from clone D9D10 (mouse 
anti-human IFN-y), and the IgG fraction of a goat antiserum directed against semipurified 
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human IFN--y (24).  100 ml of supernatant from a 6-d MLC was passed over the D9D10 
Sepharose 4 B column (0.9 X 12 cm,  10 ml/h, 4°C). The flow-through fractions, which 
did not contain any detectable human IFN-~, activity as titrated on HEp-2 cells, were then 
passed over the polyclonal goat anti-semipurified human IFN-~, column (0.9 x  12 cm, I 0 
ml/h, 4°C). After washing the column with 20 mM Tris HCI, 0.15 M NaCI, pH 8.0, the 
bound substances were eluted with 0.1  M citrate, 0.5 M NaCl, pH 2. After localization of 
the fractions containing activity of MHC class II expression induction, they were pooled 
and extensively dialyzed against 50 mM formiate buffer, pH 4, and applied to a mono-S 
column in a fast protein liquid chromatography (FPLC) system (Pharmacia Fine Chemi- 
cals), No detectable activity was present in the flow-through or wash fractions, but upon 
application of a linear gradient of 0-0.65 M NaCI, the activity was eluted as a single peak. 
2 ml of active fractions were concentrated by dialysis against PEG 20,000 to 300 tA. To 
determine the molecular mass  of the active mediator in these fractions,  100 #1 of this 
concentrated material was subjected to gel filtration on a TSK-G 3000 SW column (7.5 
x  600 mm;  LKB-Produkter AB, Bromma, Sweden). This column had been calibrated 
with a  mixture of BSA  (68  kD),  ovalbumin (43  kD),  chymotrypsinogen (25  kD),  and 
lysozyme (14.4 kD). 
Results 
MHC Class H Antigen-inducing Factor Different  from IFN-"y.  Supernatants from 
human leukocyte cultures were tested for their capacity to induce the expression 
of MHC class II antigens. For this study, four human cell types have been used. 
Human fibroblasts are known to express MHC class II antigens after incubation 
with rIFN-3, (9). Renal tubular epithelium is able to express the antigens in vivo 
in man (25-27). In addition to these cells, two human tumor cell lines, originating 
from large bowel adenocarcinomas and reported (10,  11) to express MHC class 
II antigens  in vitro only after incubation with  IFN-3,, were used as test cells to 
detect MHC class II antigen-inducing capacity. 
MLC-SN induced MHC class II antigen expression, as shown in Table I. Since 
we observed a discrepancy between the MHC class II antigen-inducing capacity 
and the titer of IFN-~' (data not shown), inactivation of IFN-3, was introduced to 
study other putative factors involved. The effect of such supernatants could not 
be due solely to  IFN-3,, since  inactivation of IFN-3~  did not abolish  the effect. 
Both acid treatment (i.e., dialysis against a buffer of pH 2), and addition of mAbs 
against human IFN-3, did not prevent the induction of MHC class II antigens on 
fibroblasts,  epithelial  cells,  and  tumor  cells.  Inactivation  of rIFN-'y by adding 
mAb abrogated the induction of the antigens by this lymphokine. 
The  dose-response  effect of the  newly  discovered  mediator  was  studied  by 
incubation of the test cells with serial dilutions of leukocyte supernatants.  Super- 
natants were dialyzed against a buffer ofpH 2 or supplemented with mAb against 
human  IFN-3,  to study solely the  influence of this factor on  the expression of 
MHC class  II antigens.  Untreated  MLC-SN  could be diluted  1:16 with  uncon- 
ditioned  medium  to  result  in  90%  of the  test  cells  expressing  MHC  class  II 
antigens. Neutralization of IFN-3' by mAb reduced the effect, though at a dilution 
of 1 : 16 the effect could still clearly be detected. Acid dialysis of the supernatants 
similarly  reduced  the  effect,  but  did  not  abolish  induction  of MHC  class  II 
antigen expression (Fig.  1). 
In addition, we studied the effect of activation ofleukocytes on the production 
of  MHC  class  II  antigen  expression-inducing  mediator.  The  supernatant  of 
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TABLE  ] 
Induction of MHC Class H Antigen Expression 
Supernatant  Treatment 
IFN-'y 
titer  Fibro-  Kidney 
(lU/ml)  blasts  epithelial 
cells 
Percent positive cells 
COLO 205  Hs703T 
MLC-SN I  None  126  50  25  90  80 
Anti-IFN-~  added  ND*  30  15  80  40 
Acid dialyzed (pH 2)  ND  20  15  30  20 
MLC-SN II  None  250  65  52  85  60 
Anti-lFN-'y  added  ND  50  36  50  60 
Acid dialyzed (pH 2)  ND  30  46  50  40 
rlFN-1,  None  100  40  35  99  95 
Anti-IFN-~, added  ND  --*  --  --  -- 
Culture medium  None  ND 
The results  of two  different MLC-SN are shown,  which are representative for a  series of  16 
supernatants tested extensively. As indicated in Materials and Methods, cells were incubated for 3 
d  with  the reagents  to be tested.  MHC class II antigen expression  was determined with mAb 
7.5.10.1. 
* Virus-protective effect of IFN-3, was not detectable. 
:~ Positive cells were not detected. 
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FIGURE  1.  MHC class II induction by incubation of COLO205 cells for 3 d with dilutions 
(open bars,  1:4 dilution; stippled bars,  1:16; striped bars,  1:64) of acid-dialyzed supernatants 
of alloactivated,  lectin-activated, and nonactivated leukocytes. Nonactivated  leukocytes (106 
cells/ml) were cultured for 6 d (as in MLC) in complete medium. MHC class II expression was 
determined with mAb 7.5.10.1. 
leukocyte  supernatants.  As  can  be  seen  in  Fig.  1,  unstimulated  leukocytes 
produced  lower  concentrations of the  factor  than  stimulated leukocytes.  The 
presence of the factor in supernatants of unstimulated leukocytes was, however, 
still  clearly  detectable  at  dilutions  of  1:4.  In  lectin-stimulated  cultures,  we 
observed concentrations comparable to concentrations produced in MLC. 
From these experiences, we conclude that a  mediator, different from IFN-3', 
with  capacity  to  induce  MHC  class  II  antigen  expression  is  present  in  the 
supernatants of human leukocytes. 
Kinetics of Appearance of  MHC Class H Antigens.  The expression of MHC class 
II  antigens  of  the  test  cell  COLO205  incubated  with  the  newly  described 
mediator or with  IFN-3' was studied with different incubation times. Results of GROENEWEGEN  ET  AL.  135 
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FI(;URE  2.  Kinetic response of MHC class II antigen expression induction by IFN-y (11) and 
by mediator from leukocyte supernatant (O).  COLO205  was used as test cell, and antibody 
7.5.10.1  was used to detect antigen expression. IFN-3, was used in a  concentration of 2  IU/ 
ml; mediator from leukocyte supernatant was used as acid-dialyzed MLC-SN at a concentration 
of 75%.  At  initiation  of the experiments MHC  class II  antigens could not  be detected on 
COLO205. 
a  representative  experiment  are presented in  Fig.  2.  It appeared that  both the 
mediator  from  MLC-SN and  IFN-3'  induced antigen  expression  that  could be 
detected as early as day 1 of incubation. The effect of IFN-~/reached its maximum 
at  day  2  and  declined  afterwards.  The  effect  of the  mediator  in  MLC-SN 
increased  till  day  2,  remained  at  a  constant  level  until  day  3,  and  declined 
thereafter.  Lower concentrations of either  IFN-3, or the mediator had reduced 
effects on antigen expression with similar kinetics (data not shown). 
Comparison with Known Factors.  In addition to acid dialyzed leukocyte SN, a 
number of well-defined factors have been studied for capacity to induce MHC 
antigens.  MHC  class  I  antigens  and  subsets  of  MHC  class  II  antigens  were 
studied.  Purified IL-1  induced a  marked increase in expression of MHC class I 
antigens (Table II). An effect of IL-1 on MHC class II antigen expression could 
not be detected.  IL-2 affected neither  MHC class  I  nor  MHC class II antigen 
expression.  IFN-3, increased both MHC class I and MHC class II expression, as 
reported (28, 29). The effect of IFN-3, on the expression of the molecules of the 
MHC  class  II  gene  complex  differed  for  the  subsets;  HLA-DR  was  clearly 
increased,  whereas only a  weak effect on  HLA-DQ was observed, as similarly 
reported by Collins et al. (29). Acid-treated MLC-SN induced a strong increase 
in MHC class I antigens and HLA-DR gene products, and a significant increase 
of HLA-DQ gene products. Results are presented in Table II. 
Interaction.  The MHC class II antigen-inducing  capacity of leukocyte super- 
natants  observed  in  the  above-described experiment  appeared  to  be  reduced 
after neutralization  of IFN-3'. This observation suggested that IFN-'y present in 
untreated supernatants  potentiated the MHC class II antigen-inducing  capacity 
of the mediator under study. In analysis of this putative interaction,  low concen- 
trations of IFN-"[ were added to titrations of acid-dialyzed MLC-SN. It appeared 
that  IFN-3,,  at  concentrations  with  submaximal  effects on  induction  of MHC 136  A  NEW  MHC  CLASS II-INDUCING MEDIATOR 
TABLE  II 
Effect of Defined Cytokines on Expression  of MHC Antigens 
Percent positive cells after incubation with: 
MHC  mAb  IL-1  rlL-2  rIFN-3'  MLC-SN  structure  + anti- 
(6 U/ml)  (100 ng/ml)  (50 IU/ml)  IFN-3'  Medium 
Class I  W6/32  99+++  95+  99++++  99++++  95+ 
Class II broad  7.5.10.1  --  --  99  95  -- 
Class II DR +  DQ Tfi39  --  --  95  95  -- 
Class II DR  Tii36  --  --  30  70  -- 
Class II DQ  Tfi22  --  --  5  60  -- 
Class II DQ  Genox 3.53  --  --  5  50  -- 
The percentage of positive cells of tumor COLO205, determined after a 3-d incubation period,  is 
indicated.  A  representative experiment from  a  series of four experiments is given.  Intensity of 
staining with anti-MHC class I marker was arbitrarily expressed and ranged from normal to very 
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FIGURE 3.  Interaction of IFN-3" and MHC class II antigen-inducing  factor. COLO205 cells 
were incubated for 3 d with dilutions  of acid dialyzed MLC-SN, to which various concentrations 
of IFN-3, were added. Percentage  of MHC class II-positive cells was determined with mAb 
7.5.10.1. 
class  II  antigen,  markedly  increased  the  expression  of MHC  class  II  antigens 
induced by the mediator, as shown in Fig.  3.  In the opposite experiment, using 
a  fixed dilution of mediator-containing  acid-dialyzed MLC-SN and a  titration of 
IFN-3,, we observed a  similar potentiating effect of IFN-3, on induction of MHC 
class II antigens by the mediator. The effect of the combined reagents exceeded 
the effects of the summation of the separate reagents. The potentiating effect of 
these two reagents explains the reduction in effect on induction of MHC class II 
antigens after neutralization of IFN-'y in leukocyte supernatants: after neutrali- 
zation, only the effect of the mediator under study was observed, unaffected by 
the potentiating effect of IFN-'y. 
Biochemical Analysis.  The unidentified mediator was biochemically character- 
ized. At first we studied whether MHC class II antigens present in the leukocyte 
supernatants could explain the  presence of MHC  class  II  antigens on  the  test 
cells  after  incubation with  leukocyte supernatants.  The  mAb  7.5.10.1,  which GROENEWEGEN ET  AL. 
TABLE III 
Binding of Mediator to Different Antibody Columns 
137 
Percent posi-  Intensity  Supernatant  Treatment  tive cells* 
MLC*SN  --  95  4 
SN I  After passage over D9D10*  95  3 
SN II  After passage over 1395*  20  1 
SN Ill  Elution from 1395  §  95  3 
* COLO205 was used as test cell, and mAb 7.5.10.1 was used as first layer for 
detection of MHC class II antigens. Response is shown as percent positive cells. 
Intensity of fluorescence is arbitrarily defined as: 4, very strong; 3, strong; 2, 
clearly detectable; and 1, respectively weak. 
* Antibody D9D10 is a mAb against human IFN-~; 1395 is a goat antiserum 
against semipurified human IFN-5' (24). 
§ Response of the  eluate after dialysis and dilution to the volume originally 
applied to column D9D10. 
appeared  to  be  highly  efficient in  removing  MHC  class  II  antigens  from  cell 
extracts (30), was bound to Sepharose beads and used for extensive immunoab- 
sorption of acid-dialyzed MLC-SN.  Subsequently, treated and  untreated  MLC- 
SN  were  titrated  in  serial  dilutions,  hnmunoadsorption  did  not  remove  the 
inducing capacity from these acid-dialyzed supernatants as shown by an experi- 
ment  in  which,  before absorption,  80%  of the  cells were positive for induced 
antigen expression, whereas after absorption,  75% of the cells were MHC class 
II-positive.  We  therefore  conclude  that  the  mediator  must  be  antigenically 
different from MHC class II antigens. 
A next step in the identification of the mediator was based on the observation 
that  the activity of the  supernatants  could not  be  neutralized by mAb  against 
IFN-~',  but  was  neutralized  by  a  polyclonal  goat  antiserum  prepared  against 
semipurified  IFN-3'  derived  from  activated  human  leukocytes (24).  In  a  first 
attempt  to  isolate  and  purify  the  mediator,  the  crude  supernatants  from  6-d 
MLC were passed consecutively over two columns of antibodies immobilized on 
Sepharose  4  B:  monoclonal  mouse  anti-human  IFN-~  on  the  first  one,  and 
polyclonal goat anti-semipurified human  IFN-~, on the second. Table III shows 
the results of one representative experiment out of a  series of six.  The second 
column  was  eluted  with  pH  2  buffer,  and  after  localization  of the  biological 
activity,  fractions  were  pooled,  dialyzed  against  formiate  buffer,  pH  4,  and 
applied  to a  mono-S column  in  an  FPLC system.  Upon application  of a  linear 
NaCI  gradient  (0-0.65  M  NaCI)  to such column,  the factor eluted as a  single 
peak of activity of antigen  expression induction at a  salt concentration of 0.45 
M  NaC1  (Fig.  4a).  This peak  fraction was  then  concentrated and  subjected  to 
high-performance gel filtration on a TSK-G 3000 SW column. A  single peak of 
activity was obtained, which eluted at a point corresponding to a molecular mass 
of 32 kD (Fig. 4 b). The results of biochemical analysis show that: (a) the activity 
is not neutralized by acid treatment,  (b) the activity is not neutralized by mAb 
against human  IFN-3', (c) the activity is antigenically different from MHC class 
II antigens, (d) the activity was neutralized by polyclonal goat antiserum against 
semipurified human  IFN-5', (e) the activity binds to cation-exchange column on 
FPLC, (f)  the activity has a molecular mass of 32 kD by FPLC gel filtration. 138  A  NEW  MHC  CLASS  II-INDUCING  MEDIATOR 
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FIGURE 4.  A, Profile on FPLC mono-S column of mediator from MLC-SN. Eluate of antibody 
column  1395,  dialyzed against sample  buffer and concentrated,  was applied  to the column. 
The  MHC class II antigen  expression-inducing  capacity was eluted  using a  0-0.65  M  NaC1 
gradient.  Activity eluted as a  single peak, highest activity at 0.45  M NaCI, and the responses 
of the fractions forming this peak have been  marked.  All other fractions showed a  negative 
reaction. The four fractions with highest activity were pooled and used for further purification. 
B,  Profile  on  FPLC  TSK-C3000  SW  column  of  mediator  from  MLC-SN.  To  determine 
molecular  mass (ordinate,  in kD) of the mediator,  protein  standards were run in parallel, as 
indicated. Pooled fractions from mono-S column (2 ml) were concentrated to 0.3 ml, and 0.1 
ml of this soIution  was applied  to the column.  A  single peak of activity, corresponding  to a 
molecular  mass of 32  kD,  was observed.  Responses  of the fractions  forming  this peak have 
been marked.  All other fractions showed a negative reaction. GROENEWEGEN  ET  AL.  139 
Discussion 
In  this  report,  we describe a  mediator,  different from IFN-y, which induces 
expression of MHC-class II antigens. The mediator is present in supernatants of 
human leukocytes and affects antigen expression on a number of different human 
cell types, such as fibroblasts, epithelial cells, and tumor cells. In the mouse (32, 
33)  suggestive evidence  has  been  produced  for  a  non-IFN-y  mediator  with  a 
similar effect on MHC class II antigen expression. A soluble product of murine 
macrophages  increases  expression  of  Ia-antigens  IFN-y  (31),  and  an  IFN--y- 
induced  tumor  macrophage  factor  with  Ia-inductive  capacity  (32)  has  been 
reported. In addition to these murine mediators, a human mediator in leukocyte 
supernatants,  different from IFN-y, has now been identified. 
The difference between the mediator, reported here, with capacity to induce 
MHC class II antigen  expression, and human IFN-y can be concluded from the 
findings discussed below. The two substances are antigenically and physicochem- 
ically different. The MHC class II antigen-inducing  mediator is resistant to acid 
treatment,  whereas  IFN-y  is  not.  The  mediator  binds  to  a  cation-exchange 
colmnn, while IFN-y does not bind to such a column under the conditions used. 
Also the molecular masses are different,  32 kD for the mediator vs.  45 kD for 
IFN-% mAbs generated against purified human IFN-% which when immobilized 
bind and  remove, and  when  in  solution neutralize  IFN-y,  neither  remove the 
mediator nor affect its activity. Furthermore,  the kinetic response of induction 
of antigen expression by the mediator from MLC-SN makes it unlikely that this 
antigen expression is caused by MHC class II molecules adhering to the test cells. 
In  addition,  absorption  with  antibody  against  MHC  class  II  antigens  did  not 
remove the activity of the mediator from the MLC-SN, excluding the possibility 
that the mediator is, itself, of that class. 
It is unlikely that the mediator is related to the IFN-~, molecule. The mediator 
does not share a physicochemical or antigenic characteristic of IFN-y, as discussed 
above. In addition, prolonged acid treatment of IFN-% resulting in inactivation 
of this  lymphokine,  did not generate  a  capacity to induce expression  of MHC 
class  II  antigens  that  could  not  be  inhibited  by mAbs  against  human  IFN-% 
Therefore,  the  mediator  described in  this  report  is not produced during  acid 
inactivation of IFN-y. Moreover, addition of mAbs against IFN-~,  to non-acid- 
dialyzed MLC-SN showed that the mediator is also present in these supernatants. 
Functionally, IFN-~,  and the new mediator are dissimilar.  IFN-y has a potent 
virus-protective  effect,  which  the  mediator  obviously lacked.  IFN-y  results  in 
only  a  minor  increase  of  HLA-DQ  antigens  (20),  whereas  the  effect  of the 
mediator on HLA-DQ antigen expression is much more pronounced, at concen- 
trations  of these two substances that  result  in  comparable effects on increased 
reactivity with  a  broadly  reactive  anti-MHC  class  II  mAb.  Subsequently, it  is 
noteworthy that the combined action of the two factors results in potentiation of 
the effect. 
The description of this mediator, different from IFN-% with capacity to induce 
expression of MHC class II antigens, sheds new light on the regulation of antigen 
expression. The interaction observed between the mediator and IFN-~, might be 
explained by enhanced  induction  (by either mediator) of receptors for itself or 
the  other  mediator,  which  would allow  fine  regulation  of antigen  expression 140  A NEW  MHC CLASS II-INDUCING  MEDIATOR 
during immunological processes. It should, however, be mentioned that the new 
mediator is capable of inducing antigen expression in the absence of even a trace 
amount  of IFN-3".  It  could therefore  be imagined  that  IFN-3'  induces  cells to 
produce the new mediator, which itself eventually induces MHC class II antigen 
expression  (27).  In  such  an  interactive  system,  many  points  of  actions  for 
modulators of MHC class II antigen expression, such as prostaglandins (13) and 
corticosteroids (14) can be envisaged. 
It  can  be hypothesized  that  the  described  mediator  is  involved  not  only  in 
vitro, but also in vivo in immunological reactions via regulation of MHC class II 
antigen expression, and might represent a  new interleukin.  Study of this factor 
in hyperimmune situations such as allograft rejection and autoimmune disease, 
and  in  hypoimmune situations  such as the bare lymphocyte syndrome and  the 
acquired immunodeficiency syndrome, all associated with changes in MHC class 
II  antigen  expression  (respectively  increased  [25,  33-36]  and  decreased  [37, 
38]), might  offer new insights into these situations and into the involvement of 
this mediator in regulation of MHC class II antigen expression. 
Summary 
In this report,  data are presented on the regulation  of MHC class II antigen 
expression  by a  mediator  present  in  supernatants  of human  mixed  leukocyte 
cultures (MLC-SN), and which is different from  IFN-3,. The capacity of super- 
natants  to  induce  antigen  expression  did  not  correspond  to  titers  of IFN-3,. 
Removal of IFN-~ using either dialysis against pH 2 or neutralizing mAb against 
human  IFN-3, did not abrogate the  MHC class II antigen  expression-inducing 
capacity of MLC-SN when tested on adenocarcinoma cell lines, kidney epithelial 
cells, and fibroblasts in vitro in an indirect immunofluorescence assay. Therefore, 
supernatants  of human  leukocytes contain  a  mediator,  different  from  IFN-3,, 
which  induces expression  of MHC class  II  antigens.  Dose-response studies  re- 
vealed that  the  mediator  is produced after allogeneic and  lectin  stimulation  of 
human  leukocytes,  and  by  unstimulated  leukocytes.  Activation  of leukocytes 
resulted  in  increased  titers of the  mediator.  The  mediator  markedly enhances 
expression of both HLA-DR and HLA-DQ antigens, whereas IFN-3' had a similar 
effect on  HLA-DR  antigens,  and  only  a  minor  effect on  HLA-DQ antigens. 
Interaction of the mediator and IFN-3, resulted in a potentiating effect of these 
two factors on MHC class II antigen expression. Biochemical analysis revealed a 
mediator,  distinguishable  by  FPLC  from  IL-1,  IL-2,  and  human  IFN-3,,  and 
which has a molecular mass of 32 kD. 
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